Femasys Inc. (FEMY)

Market Cap	18.50M -32.7%
Revenue (ttm)	2.38M +39.9%
Net Income	-11.88M
EPS	-0.24
Shares Out	60.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,594,419
Open	0.3400
Previous Close	0.3572
Day's Range	0.2854 - 0.3500
52-Week Range	0.2854 - 1.1100
Beta	-2.22
Analysts	Buy
Price Target	3.17 (+934.6%)
Earnings Date	May 8, 2026

About FEMY

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: FEMY
• Website: https://femasys.com

Financial Performance

In 2025, Femasys's revenue was $2.29 million, an increase of 40.77% compared to the previous year's $1.63 million. Losses were -$18.63 million, -1.00% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for FEMY stock is "Buy." The 12-month stock price target is $3.17, which is an increase of 934.60% from the latest price.

Price Target

$3.17

(934.60% upside)

Analyst Consensus: Buy